1. Scrip
  2. >>Business
  3. >>Deals

Ono Bulks Up MAb R&D With Second Swiss Biotech Deal

 
• By John Davis

Human-derived monoclonal antibodies targeted against neurodegenerative diseases is the subject of a deal between Japan's Ono Pharmaceutical and Zurich-based biotech Neurimmune.

Zurich
The historic center of Zurich • Source: Shutterstock

Ono Pharmaceutical Co. Ltd. has entered its second agreement this year with a Switzerland-based biotech developing novel antibodies, as it bulks up its research effort fired by the success of the checkpoint inhibitor Opdivo (nivolumab), developed in collaboration with partner Bristol-Myers Squibb Co.

This time the Japanese company has forged a collaboration with Neurimmune Holdings AG, a Zurich-based firm, which will generate and validate human-derived monoclonal antibodies against a novel therapeutic target with potential in the treatment of neurodegenerative diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.